Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment[1][2].
ChEBI: 1-linoleoyl-sn-glycero-3-phosphocholine is a lysophosphatidylcholine 18:2 in which the acyl group at position 1 is (9Z,12Z)-octadecadienoyl. It has a role as a mouse metabolite. It is a lysophosphatidylcholine(18:2/0:0) and a linoleoyl-sn-glycero-3-phosphocholine. It is functionally related to a linoleic acid.
1-Linoleoyl-2-hydroxy-sn-glycero-3-PC (LGPC) is a lysophospholipid containing linoleic acid at the sn-1 position that has been found in mouse heart, lung, liver, spleen, kidney, plasma, and serum.1 Serum levels of LGPC decrease with increasing insulin resistance and dysglycemia in humans.2
Human Endogenous Metabolite
1.Okudaira, M., Inoue, A., Shuto, A., et al.Separation and quantification of 2-acyl-1-lysophospholipids and 1-acyl-2-lysophospholipids in biological samples by LC-MS/MSJ. Lipid Res.55(10)2178-2192(2014)
2.Gall, W.E., Beebe, K., Lawton, K.A., et al.α-Hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic populationPLoS One5(5)e10883(2010)
